BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

ARGX upcoming catalysts

argenx: 0 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (0 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 8 readout(s) and 0 FDA event(s). Subscribe to ARGX (.ics).

Drugs: Empasiprubart

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
No upcoming PDUFA date or AdCom found.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
No trials in this window.

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
No FDA decision events in this window.

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11 est.P2argenx ARGXNCT06284954 A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With DermatomyositisDermatomyositis; Myositisactive not recruiting3
2026-09 est.P3argenx ARGXNCT06742190 A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor NeuropathyMultifocal Motor Neuropathy (MMN); MMNactive not recruiting154
2026-08-12P2argenx ARGXNCT06441682 A Safety and Efficacy Study of ARGX-119 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral Sclerosisterminated60
2026-07-02P2/P3argenx ARGXNCT05523167 A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.Active Idiopathic Inflammatory Myopathy; Myositis; Dermatomyositis; Polymyositis; Immune-Mediated Necompleted265
2026-03-11P3argenx ARGXNCT04225156 A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).Primary Immune Thrombocytopeniacompleted101
2026-01-12P3argenx ARGXNCT06558279 A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia GravisMyasthenia Gravis, Ocularactive not recruiting141
2025-12-15P3argenx ARGXNCT06307626 A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease.Thyroid Eye Diseaseterminated105
2025-12-15P3argenx ARGXNCT06307613 A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye DiseaseThyroid Eye Diseaseterminated102

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.